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Abstract Activation of telomerase is a critical step in the
development of about 85 % of human cancers. Levels of
Tert, which encodes the reverse transcriptase subunit of
telomerase, are limiting in normal somatic cells. Tert is
subjected to transcriptional, post-transcriptional and epige-
netic regulation, but the precise mechanism of how
telomerase is re-activated in cancer cells is poorly under-
stood. Reactivation of the Tert promoter involves multiple
changes which evolve during cancer progression including
mutations and chromosomal re-arrangements. Newly
described non-coding mutations in the Tert promoter region
of many cancer cells (19 %) in two key positions, C250T
and C228T, have added another layer of complexity to
telomerase reactivation. These mutations create novel con-
sensus sequences for transcription factors which can
enhance Tert expression. In this review, we will discuss gene
structure and function of Tert and provide insights into the
mechanisms of Tert reactivation in cancers, highlighting the
contribution of recently identified Tert promoter mutations.
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Telomere and telomerase holoenzyme
Telomeres are conserved, repetitive sequences located at
the ends of eukaryotic chromosomes which protect the
integrity of genomic DNA [1, 2]. DNA polymerase is
unable to replicate the 50 ends of chromosomes, hence,
cells require a RNA dependent DNA polymerase called
telomerase to synthesize DNA on the lagging strand [3–5].
Telomerase activity is tightly regulated and seen mainly in
germ cells, stem cells and some immune cell types which
have high proliferative needs. In contrast, somatic cells do
not display detectable telomerase activity [6]. As a result,
the chromosomes of normal somatic cells shorten
50–200 bp each replication at the telomeres due to the
problem of end replication. Thus, somatic cells are even-
tually burdened with DNA damage, replication crisis,
cellular senescence or apoptosis and can divide only lim-
ited number of times [7], whereas cells that have active
telomerase possess unlimited proliferative potential.
Telomerase was discovered by Carol Greider and Eliz-
abeth Blackburn in 1984 from ciliate Tetrahaymana [5].
Telomerase holoenzyme is comprised of a catalytic sub-
unit, hTERT (human telomerase reverse transcriptase) that
has reverse transcriptase activity and an RNA component,
hTR (human telomerase RNA component) which primes
DNA synthesis from telomere repeats. The three dimen-
sional structure of human telomerase is yet to be fully
understood. To date, it remains a challenge to purify and
crystallize the entire telomerase complex due to its low
abundance (estimated to be approximately 20–50 mole-
cules of telomerase per HEK-293 cells [8], and estimated
*250 molecules even in the highly telomerase active
cancer cell lines [9]), insolubility problems, and also the
requirement of substantial enrichment. Biochemical char-
acterization, however, suggests that hTERT and hTR are
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sufficient to recapitulate telomerase activity in vitro;
however, other cellular factors may be required for basal
in vivo activity. Mass spectrometric studies and reconsti-
tution approaches suggest that telomerase has a minimum
molecular weight of 650–670 kD and each component
appears as a dimer in the core complex including hTERT
127kd, hTR 156kd, DKC1 (dyskerin) 57 kD and Nop10
9 kD [10]. Cohen et al. also demonstrated that telomerase
can occur as a dimer [8], but in a recent study Wu et al.
showed that telomerase can also function as a monomer
and is able to add telomeric ends [11]. Furthermore, pro-
teins like Pontin, Reptin, Gar1, Nhp2, and Tcab1 were
shown to be transiently associated with the telomerase core
complex and are thought to be required for proper telom-
erase assembly and recruitment to chromosomes [12, 13].
Current knowledge proposes that the limiting factor for
telomerase activity is the level of TERT which is kept
under tight transcriptional control. Expression of Tert
mRNA in somatic cells is sufficient to reconstitute telom-
erase activity [14–16] and expression levels of Tert always
show strong correlation with telomerase activity [17, 18].
Although the level of RNA component of the telomerase
holoenzyme hTR is high in all tissues regardless of
telomerase activity [19] it is generally expressed at a lower
level in normal somatic cells as compared to cancer cells
[20]. Furthermore, half-life experiments for hTR showed a
higher turnover rate (*5 days) in somatic cells, whereas
the half-life is proposed to be between 3 and 4 weeks in
cancer and highly proliferative stem cells [20]. Most cancer
cells have more than 10,000 hTR molecules per cell
whereas quantification studies by competitive RT-PCR
assays show that hTert mRNA range between 1 and 30
molecules in human cancer cells [21]. Other quantification
studies determined that TERT protein numbers range
between 600 and 700 molecules per cell in HeLa cells [22].
It was also reported that the half-life of hTert mRNA is
only 2–3 h [23], while the half-life of active telomerase
complex appears to be approximately 24 h according to
activity assays [24]. These observations indicate that hTR
is essential for the activity of telomerase; however, the
limiting factor for telomerase activity is strictly dependent
on transcription of hTert mRNA with confounding effects
on the stability of the complex by yet unidentified factors.
On the other hand, it is noteworthy that hTR can be the
limiting factor for telomerase activity in some cases like in
the fibrosarcoma-derived HT1080 cells [25]. In general,
these results underlie the complexity of telomere mainte-
nance but overall any defect in telomere maintenance
failure results in general genomic instability. In particular,
DNA damage, increased cellular senescence and organ
degeneration are key features of aging phenomena due to
telomere shortening [26–28].
Telomerase reactivation in cancer cells
Tert expression is reactivated in*85 % of all cancers [29].
Recently numerous reports have indicated oncogenic
effects of TERT independent of its role in telomere elon-
gation [30–32]. Telomere length in mice (20–50 kb) is
greater than in humans (5–10 kb) [33–35]. However, Tert
expression is upregulated in murine breast [36] and skin
[37] tumors despite their long telomeres. These results
suggested that TERT could be playing other roles in can-
cer. Moreover, overexpression of Tert resulted in increased
cell proliferation in mammary carcinomas [38] and epi-
dermal tumors [39] in mice. Similarly, increased
expression of Tert initiated T cell lymphomas in mouse
thymocytes [40] without significant changes in telomere
length, thereby supporting its telomere independent role
[32]. Moreover, in human cancer cell lines, knocking down
Tert resulted in rapid decreases in cell proliferation and
growth [41]. Mechanistically, TERT was shown to indi-
rectly associate with promoters of NFjB target genes
interleukin (IL)-6, tumor necrosis factor (TNFa) and IL-8,
which are critical for inflammation and cancer progression,
to increase expression [42]. Expression of catalytically
inactive Tert in mouse model led to the activation of hair
follicle stem cells and induction of hair growth [43].
Although the major function of telomerase is thought to be
telomere elongation, accumulating evidence has suggested
that it can modulate expression of various genes including
target of Wnt/b-catenin [44] and NFjB signaling [42]
which affect cancer progression and tumorigenesis [45].
High throughput genomic and transcriptomic analysis has
revealed that TERT can regulate expression of about 300
genes involved in cell cycle regulation, cellular signaling,
and cell proliferation [46]. Non-canonical roles of telom-
erase have been discussed previously [31, 32], hence in this
review we will be focusing on Tert re-activation via reg-
ulation of Tert transcription.
Structure of Tert gene
The hTert gene is 42-kb long and located on chromosome 5
with 16 exons. The reverse transcriptase domain is coded by
exons 5–6–7–8–9. It has been suggested that the telomerase
transcript containing 16 exons can be spliced into 22 iso-
forms [47] but only full length Tert transcript possesses
reverse transcriptase activity essential for elongating
telomeres [48, 49]. The most commonly studied isoforms in
cancer cell lines involve exon 6–9 that partially encode the
reverse transcriptase domain [49]. Alternative spliced iso-
forms within this region produce isoforms named minus
alpha, minus beta and minus alpha/beta. Minus alpha
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isoform is spliced from a 36-bp acceptor site into exon 6
that creates dominant-negative protein without reverse
transcriptase activity [49]. Overexpression of the minus
alpha form resulted in inhibition of telomerase which leads
to either cell death or senescence [50]. The minus beta
isoform has a stop codon in exon 10 due to a frameshift after
skipping exons 7 and 8. This isoform is the most common
form among cancer cell lines. Although minus beta Tert is
subjected to non-sense mediated mRNA decay due to a
premature stop codon, it has been shown that its transcripts
can be translated into protein [51]. Listerman et al. have
reported that overexpression of the minus beta form com-
peted for hTR with endogenous telomerase activity. In their
study, Listerman and colleagues reported that overex-
pressed minus beta form conferred a growth advantage in
breast cancer cells by protecting cells from cisplatin-in-
duced apoptosis [52]. However, it remains to be determined
why cancer cells preferentially express the catalytically
inactive minus beta spliced variant of Tert. Tert isoforms
can be expressed in a given cell simultaneously; however,
ratios may differ among different cell types according to
external stimuli [51]. Deletions/insertions distant from the
RT domain also result in truncated forms of TERT protein,
the functions of which are not fully understood and need
careful characterization.
The Tert promoter has complex regulation dynamics
whereby multiple transcriptional regulatory elements play
functional roles in different contexts either individually or
interactively. Although the Tert promoter does not have
typical transcription regulatory elements like TATA and
CAAT boxes [53], it contains recognition sequences for
multiple important transcription factors such as p53, p21,
SP1, ETS, E2F, AP1, HIF1 and c-myc (Fig. 1) [54–62].
Increasing evidence shows that the level of telomerase
activity is primarily regulated through levels of Tert which
are primarily controlled by transcription of Tert gene.
Although the transcription factors stated above may alter
the ability to regulate Tert transcription under specific cell
type and physiological conditions, none of them are suffi-
cient on their own to promote immortalization of somatic
cells [63].
The Tert promoter region contains E-boxes and GC-
boxes which are the consensus binding sites for transcrip-
tion factors c-myc and SP1, respectively. These factors are
known to regulate many cellular events like cell growth,
apoptosis, and chromatin remodeling. Sp1 and c-myc
cooperatively regulate Tert expression in a cell type
specific manner [58]. One of the prominent characteristics
of Tert promoter is its high GC-rich content without a
typical TATA box or a CCAAT box. There are five GC-
boxes in the proximal Tert promoter which serve as SP1
binding port and two E-boxes (CACGTG) located in the
-165 and ?44 regions which are targetable by c-myc
and\or max proteins through their helix–loop–helix leucine
zipper domains [58]. Luciferase reporter assays reveal that
deletion of the E-box at the -165 position results in 60 %
reduction in transcriptional activity in C33A and ME180
cells but not in SiHa cells. Interestingly, mutating the other
E-box domain at position ?44 led to a 60 % reduction only
in ME180 cells. Expression of estrogen, a sex hormone,
exhibits a strong concordance with Tert transcription.
Mutations in the estrogen receptor (ER) binding sites of
Tert promoter dramatically reduced Tert transcription.
Moreover, c-myc is a known target of ER and some other
growth factors. Kyo et al. demonstrated that the effect of
estrogen was completely abrogated upon mutating E-boxes
in proximal Tert promoter [57]. Furthermore, mutating the
GC-box, located -32 from TSS, reduced transcription by
20–40 % in all cell lines and a 90 % reduction was
detected when all SP1 binding sites were mutated [58]. We
can thus conclude that Sp1 binding sites (GC-boxes) are
essential for Tert transcriptional activity and E-boxes can
accelerate transcription in a cell-type specific manner. E2F
transcription factors are involved in cell cycle regulation
and DNA synthesis [64, 65]. Ectopic expression of E2F1
repressed Tert promoter activity through inhibition of SP1
binding to DNA in cancer cells. In contrast, overexpression
of E2F1 in normal human fibroblasts increased Tert pro-
moter activity through a non-canonical E2F1 site which is
located –51 to –88 [66]. All these data suggest that E2F1
has a dual role for regulating Tert expression that requires
further investigation.
The tumor suppressor gene p53 has two binding sites
-1240 and -1877 upstream of the transcription start site
of the Tert promoter (Fig. 1). Overexpression of p53
together with SP1 leads to suppression of Tert expression
while siRNA silencing of p53 delays senescence but is
insufficient to drive cells to an immortal state [67, 68].
Overexpression of Tert is not sufficient to drive cells to the
immortal state as well. Tert expression and telomerase
activity could be enhanced by suppression of p53; how-
ever, both actions are required for immortalization of
primary human ovarian surface epithelial cells [67, 68].
NFjB is a key regulator of innate and adaptive immu-
nity which is essential for host defense [69, 70]. Activated
NFjB activates the expression of target genes that are
responsible for cell survival, proliferation, differentiation
of cells and for mounting appropriate immune responses
for host defense [71]. NFjB was also reported to be
associated with tumorigenesis and chemoresistance [71,
72]. The Tert promoter contains a NFjB binding site
upstream of its translation start site. A significant increase
in Tert expression was observed through NFjB activation
[73]. Moreover, NFjB can mediate TERT translocation to
the nucleus from the cytoplasm whilst IKK2 inhibitors can
reverse this effect in MM.1S cells [74].
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The PI3K-AKT pathway regulates various cellular
events such as proliferation and differentiation which are
important in tumorigenesis [75]. It has been reported that
Tert expression was increased by receptor tyrosine kinases
and VEGF which are controlled by PI3K in ovarian cancer
cells [76]. Moreover, Tert expression is increased
depending on two VEGF isoforms, VEGF165 and
VEGF189, which are also positively regulated upon Tert
expression regardless of its telomeric function in HeLa
cells [77]. Under physiological conditions, all of the
molecules listed above are responsible for specific cellular
processes and almost all somatic cells can achieve these
processes without reactivating their Tert gene. However,
multiple changes and impairments evolve during cancer
progression that cause chromosomal re-arrangements,
point mutations, deletions/insertions, translocations and
copy number changes.
The Tert gene has a GC rich promoter which contains
three CpG islands [53, 78]. Methylation of gene promoters
is generally known to repress transcription; however, sev-
eral studies revealed complex methylation patterns for the
active/inactive Tert promoter. The Tert promoter region
has a CpG island (positions -1100 to ?150), that is mostly
hypermethylated through specific DNA methyltransferases
(DNMTs) in cancer cells [79]. The Tert promoter between
-150 and ?150 represents a usual pattern of gene
expression. Absence of methylation causes constitutive
expression particularly in this region, hypermethylation of
50 Tert promoter prevents binding of methylation sensitive
CTCF repressor to the first exon; however, partial
hypomethylation of core promoter is required for Tert
transcription. Thus, Tert promoter methylation represents a
unique model for transcription in which hypermethylation
of cytosine islands causes inhibition of Tert expression and
this differs among different cell types [79, 80]. Hyperme-
thylation of the Tert core promoter results in low
telomerase activity and better survival rate in B cell
chronic lymphocytic leukemia [81]. On the contrary, sev-
eral studies reported that hypermethylation in telomerase
active cancer cells and hypomethylation of normal tissues
may inhibit binding of repressor elements to the Tert pro-
moter region and enhance transcriptional activity [78, 80,
82–84]. A comprehensive study by Renaud et al. demon-
strated that the Tert promoter in most cancer cell lines is
heavily methylated between -500 and -600 bp upstream
of TSS; however, they tend to be partially methylated at
TSS region [79]. The Myc/Max proteins are responsible for
recruiting Histone Acetyl transferases (HATs) to the pro-
moter regions where they can bind through their consensus
sequences [85]. Increased acetylation of H3 and H4 his-
tones creates more open chromatin structure, thereby
enhancing the accessibility of other transcription regulatory
elements. However, Mad proteins could bind to the same
E-boxes and heterodimerize with Max proteins that act
antagonistically to inhibit transcription [86].
In conclusion, Tert promoter specific methylation anal-
ysis revealed a complex/unusual methylation pattern for
the promoter region, indicating that distal and proximal
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Fig. 1 Schematic of Tert promoter region with regulatory protein
binding sites and de-novo mutations. The ?1 and ?78 (ATG)
indicates transcription start site (TSS) and first codon for TERT
protein, respectively. Dark blue regions correspond to CpG islands.
Highly recurrent mutations C228T and C250T are shown at -46 and
-68 positions from TSS. The rs2853669 polymorphism is shown in
ETS2 binding site (-167 from TSS). The sites on the promoter are
not precisely scaled
1662 S. C. Akincilar et al.
123
promoter regions have different methylation patterns that
can be partially modified due to activation or inactivation
of the Tert gene. These results highlight importance of
chromatin modifiers, especially the roles of histone methyl
transferases and demethylases in transcription dynamics.
Tert promoter mutations in cancer
Point mutations in the Tert promoter are highly recurrent in
cancer cases including glioblastoma, melanoma, urothelial,
bladder, hepatocellular carcinoma, and thyroid cancers
[87–91]. These mutations generally create new consensus
motifs for transcriptional regulators like ETS/TCF factors
and are associated with increased Tert mRNA (Fig. 2).
Therefore, point mutations in the Tert promoter could
unravel a novel mechanism for Tert reactivation in cancer
cells. Recurrent mutations have been identified in
Chr.5:1,295,228(C[T) or (CC[TT), Chr.5:1,295,250 C[T,
Chr.5:1,295,242_1,295,243CC[TT mutations in 19 % of
cancers [90].
Alternative lengthening of telomeres (ALT) is a recom-
bination-based mechanism that is activated in the absence of
telomerase activity. ALT recombination is stimulated by the
signals of double-strand DNA break and meiotic HOP2-
MND1 heterodimer induces RAD51 and DMC1 mediated
recombination [92]. ALT is observed frequently in sarcomas
(25–60 %) [93], brain tumors (10–25 %) [93], and pancreatic
neuroendocrine tumors (40 %) [92], but is rare in colon,
breast, lung, prostate and pancreas cancers. Generally, can-
cers with ALT show poor prognosis as compared to
telomerase activity. However, glioblastomas with ALT rep-
resent two- to threefold longer survival [92, 94]. Recently it
was also shown that mutations in ATRX or DAXX genes
cause increase in non-coding RNA TERRA expression
which is known to inhibit telomerase activity [95–98]. Fur-
thermore, TERRA can induce ALT through R-loop
formation in telomeres [92]. ATRX and DAXX alter
telomeric chromatin dynamics that function as a chromatin
remodeler and histone chaperone, respectively. Therefore,
cells having these mutations depend on ALT for telomere
maintenance. Interestingly, ATRX/DAXX genes and Tert
promoter mutations are mutually exclusive [87]. Besides,
there are subpopulations that display both ALT and telom-
erase mechanisms for telomere maintenance [99] which
could be a temporary/transient stage before final commit-
ment to ALT and/or telomerase as the major telomerase
mechanism depending on the cellular context and other
signaling milieu. However, there is very little knowledge
regarding the mechanism by which cells can utilize both
mechanisms or how they choose between ALT or telomerase
as a preferred mechanism to maintain their telomeres.
Hepatocellular carcinomas (HCCs) are the third leading
cause of cancer deaths and are mostly associated with
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Fig. 2 Highly recurrent mutations C228T and C250T create novel
ETS binding sites in Tert promoter. Tert promoter with wild type,
C250T and C228T are shown with their reported binding partners.
Red and green rectangular boxes indicate ETS and p52 consensus
sites on Tert promoter, respectively. ETS1/2 and p52 binds Tert
promoter harboring C250T mutation while GABP binds to Tert
promoter bearing either C250T or C228T mutation, resulting in
increased Tert mRNA expression
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hepatitis B or C virus infection while a minority is asso-
ciated with alcoholic cirrhosis, obesity and rare genetic
diseases [100, 101]. Recently, somatic mutations in the
Tert promoter region have been reported in HCC. Killela
et al. reported that 44 % of HCC tumor samples have Tert
promoter mutations (27/61) and the mutations tend to
occur relatively early during tumorigenesis [87]. Other
teams have also identified these mutations and, according
to recent reports, Tert promoter mutations are less frequent
in Eastern countries (29 to 31 % of HCC), whereas
54–60 % of HCC are mutated in Western countries [87,
102–104]. The most frequent Tert promoter mutations in
HCC (93 %) were observed at the first hot spot and consist
of G to A (-124G[A) mutations. While mutations in the
second hot spot -146 bp G to A substitutions (-146G[A)
were significantly less frequent than those found in mel-
anoma (46 %) [105]. Interestingly, Tert promoter
mutations are more frequent in older patients and signifi-
cantly associated with activating mutations of the beta
catenin pathway [103, 105]. These data suggest that
aberrant activation of the b-catenin pathway associated
with Tert promoter mutations can be one of the mecha-
nisms of telomerase reactivation in HCC. Taken together,
these data suggest that somatic mutations in the Tert
promoter region are one of the most frequently observed
genetic alterations in human HCC. Although Tert ampli-
fication and insertion of HBV in the Tert promoter has
been considered as the alternative mechanism leading to
telomerase reactivation in HCC [106, 107], identification
of Tert promoter mutations in HCCs has opened new
insights into telomerase reactivation and telomere main-
tenance in liver carcinogenesis.
Bladder cancers represent the most common urinary
tract cancer worldwide [108, 109] and recent studies have
showed that Tert promoter mutations are the most common
mutations in all stages and grades of bladder cancer with an
even distribution [110–112]. In addition, the frequency of
Tert promoter mutations detected in these studies was
higher than any earlier reported genetic alteration in any
gene in bladder cancer [112, 113]. Tert promoter mutations
were detected in both low-grade and high-grade tumors of
bladder cancer [90] and, in particular, the -124C[T
mutation was detected as the most frequent alteration in
175 (53.5 %) tumor samples [112]. In contrast, the preva-
lence of ALT in bladder cancer is as low as 1 % in 188
samples [114]. Intriguingly, Tert promoter mutations in
conjunction with the identified common polymorphism
have effects on both survival and recurrence in bladder
cancer. The common polymorphism rs2853669 from
-245 bp ATG start site in the Tert promoter acted as a
modifier of survival and recurrence in bladder cancer
patients. Bladder cancer patients who do not harbor a
variant allele of rs2853669 showed almost twofold
reduction in survival and increased disease recurrence.
Mechanistically, the variant allele of polymorphism dis-
rupts a pre-existing non-canonical ETS2 binding site in the
proximal region of the Tert promoter, adjacent to an E-box
(Fig. 1). This mechanism is in contrast to the two highly
recurrent Tert mutations which generate an ETS/TCF
binding site [112]. Disruption of the ETS2 binding site in
Tert promoter or silencing of ETS2 in breast cancer cells
has been shown to result in decreased Tert expression and
cell proliferation due to the disabling of c-Myc binding to
the E-box in Tert promoter [62]. Moreover, the variant
allele of the SNP has been previously shown to affect
telomerase expression and telomere length maintenance in
non-small lung cancers [115]. Tert promoter mutations in
combination with the polymorphism can have the potential
to serve as clinical biomarkers for prediction of survival
and recurrence in bladder cancer patients [112].
Another cancer type that harbors Tert promoter muta-
tions is urothelial cancers (UC). Borah et al. reported that
when compared to -146C[T mutation, -124C[T muta-
tion is a frequently altered lesion in 23 UC cell lines
derived from different stages and grades, including muscle
invasive and non-invasive tumors. These promoter muta-
tions provide increased Tert mRNA levels with an 18-fold
increase in median value according to qRT-PCR analyses.
Although most of these transcripts were found to be
alternatively spliced variants of Tert which lack functional
reverse transcriptase activity, both TERT protein and
telomerase enzymatic activity were higher in tumor sam-
ples harboring promoter mutations. However, compared to
the 18-fold increase in Tert mRNA level, they reported
much more modest 2-fold increases in the TERT protein
and telomerase activity that may indicate higher expression
of inactive Tert isoforms [91]. These results revealed that
Tert promoter mutations are an effective strategy to boost
the level of telomerase activity in UC which do not employ
ALT [114]. It remains to be determined why cancer cells
express catalytically inactive TERT isoforms and whether
expression of specific isoforms would change in cancers
harboring promoter mutations.
Thyroid cancer is an endocrine malignancy that can be
classified into two common groups: papillary (*85 %) and
follicular (*10 %) thyroid cancers. C228T mutation was
observed in 30 of 257 (11.7 %) papillary thyroid cancers
(PTC) and 9 of 79 (11.4 %) follicular thyroid cancers
(FTC) while interestingly, no mutations were detected in
benign thyroid tumors (0 of 85). C250T mutation was
uncommon in all groups of thyroid tumors, but is mutually
exclusive with C228T mutation. BRAF (v-Raf murine
sarcoma viral oncogene homolog B) mutation (V600E),
which activates the MAPK pathway, is commonly
observed in thyroid cancers [116]. It is also known that
cancers harboring BRAF mutation are more aggressive
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than WT counterparts [117]. Tert C228T mutation was
correlated with BRAF mutation and it was reported that 19
of 104 cases (18.3 %) coexist in PTC while 11 of 153
(7.2 %) BRAF negative tumors exclusively harbor C228T
mutation. In a separate study, BRAF mutation was found to
exist in 19 of 30 (63.3 %) C228T mutant tumors, and 85 of
227 (37.4 %) C228T negative tumors [118]. Similarly,
Vinagre et al. investigated Tert promoter mutations in large
thyroid cancers categorized as normal, benign and malig-
nant lesions. Tert promoter mutations were only detected in
malignant lesions in 11 % of PTCs, 14 % of FTCs, 21 % of
poorly differentiated thyroid carcinomas and 13 % of
anaplastic carcinomas. The majority of these mutations
were C228T. Correlation analysis revealed that Tert pro-
moter mutations were highly associated with larger tumor
size, older patients, lymph node metastasis and BRAF
(V600E) mutation. Tert mRNA was also significantly
higher in patients with BRAF and Tert promoter mutation
[90]. These results indicate that Tert promoter mutation is
prevalent in more aggressive tumors.
Gliomas are the most common cancer of the central
nervous system (CNS), with four major subtypes including
primary glioblastoma, astrocytoma, oligodendriogliomas
and oligoastrocytomas [119]. Primary glioblastomas are
the most common glioma among adults with very poor
survival rates. It was shown that 83 % of the 78 tumors
analyzed harbored Tert promoter mutations which were
correlated with high Tert expression levels and poorer
patient survival [87]. Remarkably, EGFR amplification, a
common phenomenon in GBM tumors, was observed to be
mutually exclusive with Tert mutations [87]. Astrocytomas
are another frequently occurring glioma subtype. This
group displays rare Tert promoter mutations (10 %);
however, IDH1 and IDH2 mutations (75 %) as well as
ATXR mutations (70 %) are common, which is also cor-
related with the high prevalence of ALT (63 %) in these
gliomas. In contrast to astrocytomas, oligodendrogliomas
frequently (78 %) harbor Tert promoter mutations. Inter-
estingly, more than 90 % of this glioma subtype seems to
strictly depend on mutations either in ATRX gene or Tert
promoter for telomere maintenance, indicating the
requirement of these genetic alterations for tumorigenesis
of this subtype. Oligoastrocytomas have features of both
astrocytomas and oligodendriogliomas and have a 25 %
frequency of Tert mutations [87].
Recently it was reported that 15 % of grade II and III
glioblastoma patients had Tert promoter mutations in their
genome; however, the mutation rate increases dramatically
in grade IV patients to 76 % [90]. Patients with Tert pro-
moter mutations in combination with common gene
alterations found in gliomas including IDH mutations and
1p19q deletion showed poorer survival rate as compared to
patients without Tert mutations [120]. This is a clear
indication that these promoter mutations increase the
malignancy of gliomas through Tert activation.
Although a majority of neuroblastoma tumors possess
Tert promoter mutations, alternative genetic alterations like
copy number increase and Tert gene re-arrangements
leading activation of Tert have been observed in cancer
patients. Genome wide sequencing analysis of neuroblas-
toma patients revealed recurrent Tert gene re-arrangements
occurring at 5p15.33 region leading to a juxtaposition of
the Tert promoter with strong enhancers. Tert re-arrange-
ment was observed in 13 % (28 of 217) of high-risk
neuroblastoma tumors. Patients with these re-arrangements
had increased Tert mRNA expression and poor survival
rate. Moreover, multiple active enhancer clusters were
detected in the translocated regions adjacent to Tert rear-
rangements indicating that translocation of cis-acting
regulatory elements can cause up-regulation of Tert
expression [121]. These results suggest that genomic
rearrangements rather than Tert copy number changes
could be the major cause of aberrant Tert expression in
neuroblastoma in addition to Tert promoter mutations.
Similar observations have been shown in melanoma
patients and cell lines. Melanomas frequently harbor
mutations in oncogenes like BRAF, NRAS (neuroblastoma
RAS viral oncogene homolog), KIT (v-kit Hardy–Zucker-
man 4 feline sarcoma viral oncogene homolog) and tumor
suppressors CDKN2A and PTEN. These mutations occur
according to cancer stage. Recently a high frequency of
Tert promoter mutations was reported in melanoma
patients and cell lines by several groups [90, 122–124].
Horn et al., observed Tert promoter mutations in a mela-
noma-prone family where all members developed
melanomas at early ages. Furthermore, the same group
reported that 125 of 168 (74 %) metastatic melanoma cell
lines carry Tert promoter mutations which are located 124
(C[T), (CC[TT), 138 and 146 bp upstream from the ATG
start codon with frequencies of 27.4, 4.2, 4.8 and 38.1 %,
respectively [122]. Whole genome sequencing analyses
revealed that Tert promoter mutations are the most frequent
mutations after BRAF and NRAS genes in melanomas
[123]. Both groups observed two- to fourfold increases in
Tert expression by Luciferase reporter assays due to novel
ETS site generation upon mutations [122, 123]. It is
noteworthy that Tert mutations are more common in
patients with BRAF and/or NRAS mutations [124] and Tert
mRNA levels are higher when Tert and BRAF mutations
coexist [90].
Recently two independent groups have studied binding
of ETS factors on mutated sites. Bell et al. identified sev-
eral ETS factors such as ELF1, ETS1 and ETV4 which can
bind to the mutation site significantly; however, GABP was
enriched more in mutation regions together with PolII
(Fig. 2). In addition, chromatin immunoprecipitation
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experiments for GABP did not show enrichment in K562,
A549, HeLa, MCF-7 cells which do not harbor the Tert
promoter mutation. GABP knockdown also led to a rapid
decrease in Tert transcription [125]. Li et al. identified
binding partner p52 for ETS factor—ETS1/2 to drive Tert
transcription in cells containing C250T Tert mutation
(Fig. 2). They showed that non-canonical NFjB signaling
is necessary to drive Tert transcription particularly in
C250T mutant Tert promoter by direct interaction with
ETS factor. Consistent with their biochemical data, knock
down of p52 during non-canonical NFjB activation abol-
ished tumorigenesis in C250T-mutant glioblastoma cells
transplanted mouse models. C250T mutation creates a half
site NFjB consensus sequence (50-GGGGG-30 or 50-
GGAA-30) and increased p52 binding was observed in the
mutant promoter as compared to WT Tert sequence in
electrophoretic mobility shift assays (EMSA). The group
further demonstrated that Tert expression increased upon
binding of p52 to the novel half site in cells harboring
C250T but not C228 mutation. Moreover, ETS1/2
heterodimerized with p52 at C250T region and coopera-
tively activated Tert gene expression, thereby
demonstrating the non-canonical role of NFjB in telom-
erase reactivation in cancer cells harboring Tert promoter
mutations [126].
Conclusion
Reactivation of telomerase has been considered as a strat-
egy for telomere maintenance and is a major hallmark of
cancer. Telomerase reactivation mostly depends on the
amount of TERT in the cell since there are sufficient
amounts of other telomerase complex molecules as sum-
marized above. Therefore, increases in TERT could be
substituted by increasing gene copy number as in HeLa
cells (five copies), overexpression of oncogenes that can
bind its promoter for transcription like c-Myc or using
alternative splicing to form catalytically active/inactive
proteins.
More importantly, Tert promoter mutations which create
new consensus sequence for ETS and NFjB binding result
in increased transcription of Tert mRNA. It is also note-
worthy that these mutations could lead to chromatin
conformation changes by novel short, middle and long
distance interactions, which could, in turn, directly regulate
the Tert gene and possibly other genes simultaneously.
Since these mutations are highly recurrent in many cancer
types and occur at high frequency, the mechanisms
underlying regulation of Tert expression at its promoter
need to be deciphered. We can speculate that the presence
of these mutations could modulate core transcriptional
machinery by recruiting additional factors to the Tert
promoter to regulate expression of specific isoforms of Tert
transcript preferentially in cancers. Furthermore, it would
be interesting to determine why mutations occur persis-
tently in the -146 and -124 positions in a wide range of
various cancer types. Recently, Chiba et al. revealed that
introducing any of the three most frequent Tert promoter
mutations using CRISPR/Cas9 genome editing in human
embryonic stem cells did not increase Tert expression,
activity or telomere length. However, when these engi-
neered stem cells were differentiated to either fibroblast or
nerve cells, all of the Tert promoter mutations, without any
additional oncogenic mutations, prevented silencing of the
Tert promoter and resulted in enhanced Tert expression,
telomerase activity, telomere length and growth compara-
ble to cancer cell lines [127]. These results indicate that
Tert promoter mutations do not affect already active pro-
moters but prevent proper silencing of the Tert gene in
differentiated cells. Recently, it was shown that cancer cell
lines harboring Tert promoter mutations represent display
histone marks [128]. It would be intriguing to speculate
that the presence of Tert promoter mutations may affect
recruitment of epigenetic modulators and enhancers to the
Tert promoter to drive Tert expression.
Since Tert promoter mutations are not present in stem
and healthy proliferating cells, it will be crucial to decipher
the mechanistic pathways which regulate Tert gene silenc-
ing and understand how they are affected by these promoter
mutations. It will also be a wise strategy to identify specific
therapeutic approaches targeting only Tert promoter muta-
tions so that only tumor cells but not telomerase positive
stem cells are eliminated in cancer patients.
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